LoQus23
We are developing small molecule somatic expansion inhibitors for the treatment of Huntington’s Disease and other triplet repeat expansion diseases.
Series A ·
Amount not disclosed in a source on record.
All 2 rounds ↓Signals
Website registeredMar 26, 2019 (7 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | undisclosed | — | fundraisingfox.com | |
| Seed | undisclosed | — | fundraisingfox.com |
Timeline
- Website created
Founders and team
DR
David Reynolds Founder
Investors
Companies like LoQus23
SStorm Therapeutics$56M Series B+ · Apr 2026
LLoxagen
CCellCentric$220M Series B+ · May 2026
GGrannus Therapeutics
AAugustine Therapeutics$85M Series A · Mar 2025
NNoema PharmaSeries B+ · Nov 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/loqus23 (get a free API key).